Skip to content

Yuan Liu

Department of Cardiology, The Second Affiliated Hospital, Chongqing Medical University, No. 288, Tianwen Avenue, Chayuan, Nan'an District, Chongqing, China.

2 papers in the library · 4 citations · publishing 2025

Papers

Drug-related suicidal ideation in the K-12 population: a real-world pharmacovigilance study of the FDA adverse event reporting system (FAERS) database.

Journal of psychiatric research August 1, 2025 Yaxin Ju, Yuan Liu, Li Tan et al. 3 citations

An analysis of the FDA Adverse Event Reporting System from 2004 to 2023 identified 21 drugs potentially linked to increased suicidal ideation risk in children aged 6–17. Among 4,779 valid cases, montelukast was the most commonly reported drug, and esketamine showed the highest statistical signal. The most common indications were ADHD, depression, acne, and asthma. Cumulative incidence of suicidal ideation within 90 days was 51.6% in males and 58.8% in females; within 360 days it was 76.9% and 85.3%, respectively. The findings suggest specific medications may pose elevated risk, but further research is needed to confirm.

Exploring Esketamine's Therapeutic Role for Perinatal Depression via TASK-1 Tandem Pore Potassium Channels.

ACS chemical neuroscience July 29, 2025 Lin Zhu, Ji Chen, Yuan Liu et al. 1 citation

Esketamine significantly lowers depression scores in new mothers with perinatal depression, as shown in a clinical trial with 298 full-term pregnant women. The antidepressant effect is linked to modulation of TASK-1 potassium channels, which reduces neuroinflammation and depressive-like symptoms. Studies in mouse models and cultured neurons confirm that esketamine acts through these channels to alter synaptic plasticity proteins. This work identifies a specific neural pathway for esketamine's rapid action, offering a promising therapeutic avenue for perinatal depression.